Want to see BHST full AI Analyst Report?
BHST Stock Chart & Stats
$1.92
$0.11(5.73%)
At close: 4:00 PM EDT
$1.92
$0.11(5.73%)
Day’s Range― - ―
52-Week Range$1.82 - $12.80
Previous Close$2.03
Volume137.38K
Average Volume (3M)78.84K
Market Cap
$48.96M
Enterprise Value$95.63
Total Cash (Recent Filing)$19.17M
Total Debt (Recent Filing)$16.42M
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Aug 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding22,667,843
10 Day Avg. Volume86,360
30 Day Avg. Volume78,844
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)3.75
Price to Sales (P/S)2.77
P/FCF Ratio-9.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside525.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$42.89M
Bulls Say, Bears Say
Bulls Say
Proprietary Botanical Synthesis & CDMO MilestonesBioHarvest's proprietary botanical synthesis platform has cleared key technical hurdles and converted R&D into commercial CDMO contracts. Retaining equity stakes (e.g., 20% in a $1.2M fragrance Stage‑2) creates potential royalty and long‑term revenue streams, strengthening a durable technology-based competitive advantage in high-value botanicals.
Strong Revenue Growth And Improving Gross MarginSustained top-line growth and materially improved gross margins (~59%) reflect product-market fit for both D2C and CDMO offerings. Higher gross margins improve scalability economics, narrowing the gap to profitability as fixed costs are leveraged with volume, supporting durable margin sustainability if revenue growth persists.
Material Cash Build And Improved LeverageA stronger cash position and more controlled leverage reduce near-term financing pressure. Improved balance sheet metrics give management runway to invest in CDMO scale and D2C marketing, lowering short-term dilution and execution risk while enabling strategic investments to capture long-term, royalty-bearing projects.
Bears Say
Persistent Net Losses And Negative Cash FlowDespite revenue and margin progress, ongoing TTM losses and negative operating/free cash flow indicate structural cash burn. This reduces self-funding ability, increases reliance on external capital or slower scaling, and makes long-term execution sensitive to fundraising conditions until operating cash flow sustainably turns positive.
Manufacturing Capacity Dependence And Capital UncertaintyScaling CDMO revenue and commercializing saffron/fragrance programs hinge on a new facility (target H2 2027). Delays or higher-than-expected build costs could throttle revenue conversion, force suboptimal outsourcing, and require incremental capital, making long-term growth and margin assumptions execution-sensitive.
Early-stage Technical And Commercialization Risk For Novel AssetsKey innovation areas (e.g., plant extracellular vesicles/exosomes) are still in characterization, with uncertain downstream processing and market fit. These R&D and validation risks could delay or limit high-margin, royalty-bearing opportunities and require sustained investment, tempering the durability of future revenue streams.
BioHarvest Sciences News
BHST FAQ
What was BioHarvest Sciences’s price range in the past 12 months?
BioHarvest Sciences lowest stock price was $1.82 and its highest was $12.80 in the past 12 months.
What is BioHarvest Sciences’s market cap?
BioHarvest Sciences’s market cap is $48.96M.
When is BioHarvest Sciences’s upcoming earnings report date?
BioHarvest Sciences’s upcoming earnings report date is Aug 11, 2026 which is in 7 days.
How were BioHarvest Sciences’s earnings last quarter?
Currently, no data Available
Is BioHarvest Sciences overvalued?
According to Wall Street analysts BioHarvest Sciences’s price is currently Undervalued.
Does BioHarvest Sciences pay dividends?
BioHarvest Sciences does not currently pay dividends.
What is BioHarvest Sciences’s EPS estimate?
BioHarvest Sciences’s EPS estimate is -0.12.
How many shares outstanding does BioHarvest Sciences have?
BioHarvest Sciences has 22,667,843 shares outstanding.
What happened to BioHarvest Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioHarvest Sciences?
Currently, no hedge funds are holding shares in BHST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioHarvest Sciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (525.00% Upside)
$12.00 (525.00% Upside)
Blogger Sentiment
Bullish
BHST Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
71.33%
Trailing 12-Months
Company Description
BioHarvest Sciences
BioHarvest Sciences Inc. functions as a biotechnology firm with operations segmented into Nutraceuticals and Pharmaceuticals. A key innovation is its proprietary botanical synthesis platform technology, which allows for the cultivation of active ingredients found within plant enzymes or cells. The company harnesses this advanced technology to craft evidence-based and clinically validated therapeutic products for both its nutraceutical and pharmaceutical offerings. Beyond its own development, it also provides contract development and manufacturing services. Its product portfolio includes various wellness items, notably VINIA, a dietary supplement derived from red grape cells, which delivers the full spectrum of polyphenols naturally present in red grapes. The company conducts business in Israel and the United States, with its corporate base in Vancouver, Canada.
BHST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed solid technological and commercial progress — notable CDMO milestones (Stage 1 completions, a $1.2M Stage 2 fragrance contract with 20% retained ownership, and Saffron Stage 1 advancement), stronger cash position, and clear D2C product traction (VINIA Blood Flow Hydration, strong reviews, active users). However, near-term financials show continued net losses, increased operating and marketing spend, and a deliberate D2C marketing reset that temporarily depressed revenue. Execution risks remain around manufacturing capacity timing (new facility target H2 2027), potential future capital needs, and early-stage validation for novel assets. Overall the positives (milestones, cash build, pipeline, product traction and reiterated guidance) outweigh the short-term headwinds and uncertainties, but successful execution over the next quarters — especially H2 2026–2027 — will be critical to realize the opportunities.View all BHST earnings summariesBHST Stock 12 Month Forecast
Average Price Target
$12.00
▲(525.00% Upside)
Technical Analysis
Ownership Overview
0.08% Insiders
0.05% Mutual Funds
1.48% Other Institutional Investors
98.39% Public Companies and
Individual Investors